Objective: To evaluate clinical and functioning outcomes of risperidone long-acting injection (RLAI) treatment in patients with schizophrenia enrolled in the electronic-Schizophrenia Treatment Adherence Registry (e-STAR) from Czech Republic and Slovakia. Methods: e-STAR is an international, long-term, prospective, observational study of patients with schizophrenia who commence RLAI treatment. Data are collected retrospectively for one year and prospectively every three months for two years. Clinical outcomes were measured by Clinical Global Impression-Severity (CGI-S) scale and patient functioning was assessed using Global Assessment of Functioning (GAF) scale. This interim report is based on data from patients who have completed their 18-month follow-up visit. Results: To date, a total of 1324 patients have been enrolled in e-STAR from the Czech Republic and Slovakia; 296 patients with at least 18-months of data available (97.3% still on RLAI) were included in this analysis. Of the 296 patients, 53.7% were male with a mean age of 37.6±12.0 years and a mean time since diagnosis of 9.6±9.0 years. Mean CGI-S score significantly decreased from 4.6±1.1 at baseline to 2.9±1.0 at 18 months (p<0.001). Proportion of patients with not ill/very mild/mild illness increased from 13.5% to 75.6% and that of patients with marked/severe/extremely severe decreased from 48.8% to 6.3% (p<0.001) compared to baseline. Meanwhile, patient global functioning has significantly improved as the mean GAF score increased significantly from 49.9±15.2 at baseline to 73.8±14.5 at 18 months (p<0.001). Conclusion: Significant improvements in disease severity and functioning from baseline were observed during 18-month treatment with risperidone long-acting injection in patients with schizophrenia.